Skip to main content

Table 1 Relationship between PIK3CA mutation status and standard clinicopathological parameters a

From: Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition

  Number of patients (% in brackets)  
Demographic characteristics Total population number (%) PIK3CA WT, n(%) PIK3CA mutation, n(%) P-valueb
Totals 85 (100) 60 (70.6) 25 (29.4)  
Mean age (±SD), yr 70.9 (8.5) 71.0 (8.4) 70.7 (9.0)  
Histological grade 0.033
  Number available 70 47 23  
  1 13 (18.6) 5 (10.6) 8 (34.8)  
  2 43 (61.4) 30 (63.8) 13 (56.5)  
  3 14 (20.0) 12 (25.5) 2 (8.7)  
  Unknown 15    
Stage (n = 85)    0.780
  2 48 (56.5) 33 (55.0) 15 (60.0)  
  3 28 (32.9) 21 (35.0) 7 (28.0)  
  4 9 (10.6) 6 (10.0) 3 (12.0)  
Lymph nodes (n = 85)    0.472
  Positive 35 (41.2) 23 (38.3) 12 (48.0)  
  Negative 50 (58.8) 37 (61.7) 13 (52.0)  
Tumour sizec (n = 76)    0.610
  T2 48 (63.2) 33 (61.1) 15 (68.2)  
  T3 28 (36.8) 21 (38.9) 7 (31.2)  
Histology     0.725
  Number available 58 38 20  
  Ductal 44 (75.9) 29 (76.3) 15 (75)  
  Lobular 8 (13.8) 6 (15.8) 2 (10)  
  Other 6 (10.3) 3 (7.9) 3 (15)  
  Unknown 27    
ERα status    1.000
  Number available 83 25 58  
  Negative 0 0 0  
  Positive 83 (100) 25 (100) 58 (100)  
  Unknown 2    
PgR status     0.49
  Number available 83 58 25  
  Negative 11 (12.9) 9 (15.5) 2 (8)  
  Positive 72 (86.7) 49 (84.5) 23 (92)  
  Unknown 2    
HER2 status     1.000
  Number available 82 57 25  
  Negative 69 (84.1) 48 (84.2) 21 (84)  
  Positive 13 (15.9) 9 (15.8) 4 (16)  
  Unknown 3    
Subtype     0.039
  Number available 46 23 13  
  Luminal A 22 (47.8) 11 (47.8) 11 (84.6)  
  Luminal B 24 (52.2) 12 (52.2) 2 (15.4)  
  1. aER, Oestrogen receptor; HER2, Human epidermal growth factor receptor 2; PgR, Progesterone receptor; PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α; WT, Wild type. bFisher’s exact test. P-value relates to the comparison between wild type and mutation. cMeasurements of tumour size were taken by caliper (n = 45), magnetic resonance imaging (n = 2), physical examination (n = 25) or ultrasound (n = 4). T4 and T4a patients (n = 1 and n = 8, respectively) were excluded from the analysis of tumour size.